Information  X 
Enter a valid email address

Onzima Ventures PLC (ONZ)


Wednesday 20 April, 2016

Onzima Ventures PLC

Filing of Patents by 49% - owned N4 Pharma

RNS Number : 6888V
Onzima Ventures PLC
20 April 2016

Onzima Ventures PLC

("Onzima" or the "Company")

Filing of Patents by 49%-owned N4 Pharma

Onzima is pleased to announce that N4 Pharma Limited ("N4 Pharma") its 49%-owned investee company has filed a range of 45 patents to allow N4 Pharma to reformulate sildenafil to greatly improve the pharmacological profile of this global drug.


The patents include novel cocrystals of sildenafil discovered by N4. They also include the first tranche of the patents recently acquired from OPAL IP which greatly extend the scope of the reformulation such that N4 Pharma are able to not only improve the onset of action but maintain the level of the drug in its therapeutic window from dose to dose, therefore also extending the drugs length of action.

N4 Pharma CEO Nigel Theobald commented:

"This is a major step forward for N4 Pharma and clearly demonstrates our strategy of securing strong intellectual property that we can then take forward commercially with the right partner.


In effect we are able to combine the onset advantages of Stendra and the long lasting advantages of Cialis into a new reformulation of sildenafil that will give the world's most popular drug for erectile dysfunction a new lease of life with strong long term patent protection.


This is the first example of how we plan to combine the patent skills from OPAL IP with the reformulation skills of N4 pharma and we will seek to repeat this with a number of other well-known drugs.


Our next step for this product is to open discussions with some of the leading formulation and pharmaceutical companies to partner us in bringing this new drug to market"


For further information please contact:    


Onzima Ventures PLC                                                    Tel:  +44 (0) 1732 366 561

Gavin Burnell, Luke Cairns


Nominated Adviser

Cairn Financial Advisers LLP                                        Tel:  +44 (0) 20 7148 7900       

Sandy Jamieson, Liam Murray



Peterhouse Corporate Finance Limited                Tel:  +44 (0) 20 7469 0930   

Guy Miller, Lucy Williams



This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t